L 
Lepu Scientech Medical Technology Shanghai Co 2291.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
14.48
+1.54%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥614.8m
FY2019FY2025
Net income
CN¥279.2m
FY2019FY2025
Free cash flow
CN¥168.5m
FY2019FY2025
Shareholders' equity
CN¥2.37bn
FY2019FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | CN¥614.8m | CN¥471.6m | CN¥325.9m | CN¥247.7m | CN¥222.6m | CN¥148.2m | CN¥116.5m |
| Gross profit | CN¥520.5m | CN¥424.0m | CN¥288.8m | CN¥219.7m | CN¥197.5m | CN¥133.1m | CN¥102.8m |
| Research and development | CN¥67.7m | CN¥58.0m | CN¥62.1m | CN¥53.9m | CN¥41.4m | CN¥39.0m | CN¥25.8m |
| Operating income | CN¥322.0m | CN¥286.1m | CN¥158.7m | −CN¥1.7m | CN¥76.4m | CN¥76.5m | CN¥58.0m |
| Net income | CN¥279.2m | CN¥245.6m | CN¥151.5m | −CN¥19.8m | CN¥58.7m | CN¥68.8m | CN¥51.9m |
| Diluted earnings per share | 0.81 | 0.71 | 0.44 | -0.06 | 0.18 | 0.25 | 0.19 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Total assets | CN¥2.45bn | CN¥2.43bn | CN¥2.31bn | CN¥1.81bn | CN¥1.12bn | CN¥332.5m | CN¥308.6m |
| Cash and short-term investments | CN¥1.35bn | CN¥1.31bn | CN¥1.48bn | CN¥1.20bn | CN¥713.5m | CN¥19.5m | CN¥16.9m |
| Total liabilities | CN¥71.6m | CN¥100.1m | CN¥69.6m | CN¥65.1m | CN¥734.5m | CN¥78.9m | CN¥76.7m |
| Debt | CN¥1.1m | CN¥1.5m | CN¥959,800 | CN¥3.3m | CN¥6.2m | CN¥116,000 | CN¥369,000 |
| Shareholders' equity | CN¥2.37bn | CN¥2.33bn | CN¥2.24bn | CN¥1.74bn | CN¥385.2m | CN¥253.6m | CN¥231.9m |
| Shares outstanding | 347m | 347m | 347m | 331m | 325m | 277m | 277m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥257.5m | CN¥259.1m | CN¥191.3m | CN¥65.5m | CN¥105.3m | CN¥59.1m | CN¥54.5m |
| Capital spending | −CN¥89.0m | −CN¥99.5m | −CN¥113.5m | −CN¥83.4m | −CN¥91.8m | −CN¥15.7m | −CN¥3.3m |
| Free cash flow | CN¥168.5m | CN¥159.6m | CN¥77.7m | −CN¥17.8m | CN¥13.4m | CN¥43.4m | CN¥51.2m |
| Dividends paid | −CN¥250.4m | −CN¥226.8m | — | — | −CN¥320.0m | — | — |
Latest quarters
By quarter end
| Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥356.2m | CN¥230.9m | CN¥383.9m | CN¥222.5m | CN¥249.1m | CN¥160.0m | CN¥193.2m | CN¥122.9m |
| Gross profit | CN¥292.2m | CN¥189.4m | CN¥331.1m | CN¥197.4m | CN¥226.7m | CN¥141.3m | CN¥171.8m | CN¥110.2m |
| Operating income | CN¥185.9m | CN¥76.6m | CN¥245.4m | CN¥122.2m | CN¥163.9m | CN¥76.7m | CN¥91.9m | −CN¥36.1m |
| Net income | CN¥168.3m | CN¥67.2m | CN¥212.0m | CN¥105.3m | CN¥140.2m | CN¥75.4m | CN¥88.6m | −CN¥44.1m |
| Diluted earnings per share | 0.49 | 0.19 | 0.61 | 0.30 | 0.40 | 0.22 | 0.26 | -0.13 |
| Cash from operations | — | CN¥68.0m | CN¥211.0m | CN¥138.0m | CN¥120.0m | CN¥119.0m | CN¥61.0m | CN¥12.0m |
| Capital spending | — | −CN¥42.0m | −CN¥50.0m | −CN¥63.0m | −CN¥36.0m | −CN¥2.0m | −CN¥1.0m | −CN¥3.0m |
| Free cash flow | — | CN¥26.0m | CN¥161.0m | CN¥75.0m | CN¥84.0m | CN¥117.0m | CN¥60.0m | CN¥9.0m |
| Total assets | CN¥2.61bn | CN¥2.45bn | CN¥2.65bn | CN¥2.08bn | CN¥2.15bn | CN¥1.99bn | CN¥2.20bn | CN¥1.81bn |
| Cash and short-term investments | CN¥1.50bn | CN¥1.35bn | CN¥1.54bn | CN¥1.13bn | CN¥1.32bn | CN¥1.27bn | CN¥1.42bn | CN¥1.20bn |
| Debt | CN¥944,426 | CN¥1.1m | CN¥1.3m | CN¥1.5m | CN¥2.7m | CN¥2.4m | CN¥2.1m | CN¥3.3m |
| Shareholders' equity | CN¥2.33bn | CN¥2.37bn | CN¥2.30bn | CN¥2.00bn | CN¥1.88bn | CN¥1.93bn | CN¥2.14bn | CN¥1.74bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 35.4% | 32.9% | — |
| Operating income | — | 33.3% | — |
| Net income | — | 32.3% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 86.9% | 87.5% | 87.8% | — |
| Operating margin | 56.0% | 46.1% | 45.2% | — |
| Net margin | 48.3% | 39.5% | 38.6% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Price to earnings | 17.2 | 21.3 | 53.9 | -414.4 |
| Price to sales | 7.8 | 11.1 | 25.1 | 33.1 |
Dividends and splits
Per share, in the currency the company pays
Paid for 2 years. Last went ex-dividend on 26 May 2025.
| FY2025 | FY2024 | |
|---|---|---|
| Paid in the year | 0.674 | 0.626 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.